TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15504872

Group type: EXPERIMENTAL
Intervention: Intrarectal administration of quinine (16 or 20 mg/kg)
Number of subjects: 60
Study: 11679506

Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl oestradiol plus 75 microg gestodene
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl oestradiol plus 150 microg desogestrel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pill users
Number of subjects: 60
Study: 9477463

Group type: EXPERIMENTAL
Intervention: Centrifugal pump (Group B)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Centrifugal pump with heparin-coated circuit (Group C)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Roller pump (Group A)
Number of subjects: 61
Study: 7944879

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluphenazine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3364308

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin B complex and vitamin C preparation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonsupplemented postoperative controls
Number of subjects: 28
Study: 31662162

Group type: EXPERIMENTAL
Intervention: 15-minute moderate-intensity exercise before memory encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15-minute moderate-intensity exercise during memory consolidation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 0
Study: 29178685

Group type: EXPERIMENTAL
Intervention: Multiple levels of antidepressant treatment
Number of subjects: 1953

Group type: EXPERIMENTAL
Intervention: Predictors of delayed remission
Number of subjects: 1953

Group type: EXPERIMENTAL
Intervention: Final predictive model
Number of subjects: 1953
Study: 25760423

Group type: EXPERIMENTAL
Intervention: Genetically engineered chondrocytes (6×10^6 cells)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Genetically engineered chondrocytes (1.8×10^7 cells)
Number of subjects: 27
Study: 23962096

Group type: EXPERIMENTAL
Intervention: Single-use, air-cushioned face mask (AM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reusable silicone face mask (SM)
Number of subjects: 32
Study: 21872708

Group type: EXPERIMENTAL
Intervention: Temporary gastric electrical stimulation (tGES) for 72 hours during session 1
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Temporary gastric electrical stimulation (tGES) for 72 hours during session 2
Number of subjects: 58

Group type: COMPARATOR
Intervention: Overall treatment effect across sessions
Number of subjects: 58
Study: 19472534

Group type: EXPERIMENTAL
Intervention: Biaxial microincisional cataract surgery with enlargement of one incision to 2.8 mm
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-surgical control group
Number of subjects: 50
Study: 17935024

Group type: EXPERIMENTAL
Intervention: Unilateral laminectomy for bilateral decompression
Number of subjects: 50
Study: 15060899

Group type: EXPERIMENTAL
Intervention: Electrolytic iron (66 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced iron (66 mg/kg)
Number of subjects: 0
Study: 11135169

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Cardiac valve operations
Number of subjects: 266
Study: 9701188

Group type: EXPERIMENTAL
Intervention: 60 IU vitamin E/d
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 200 IU vitamin E/d
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 800 IU vitamin E/d
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 8025741

Group type: EXPERIMENTAL
Intervention: ganciclovir 5 mg/kg once a day 5 d/wk (Group G)
Number of subjects: 25

Group type: COMPARATOR
Intervention: acyclovir 800 mg four times a day (Group A)
Number of subjects: 25
Study: 2557572

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin 15,000 AXaU/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin 7,500 AXaU/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Calcium heparin 5000 I.U. t.i.d.
Number of subjects: 90
Study: 4548092

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil (5 FU)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard endocrine therapy
Number of subjects: 8
Study: 29654980

Group type: EXPERIMENTAL
Intervention: Pain Education with Clinical Hypnosis (PE + CH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pain Education (PE) alone
Number of subjects: 100
Study: 28062311

Group type: EXPERIMENTAL
Intervention: TRPA1 antagonist A-967079
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: TRPV1 inhibitor BCTC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amiloride (acid-sensing ion channel blocker)
Number of subjects: 15

Group type: COMPARATOR
Intervention: pH 4.3 continuous intraepidermal injection
Number of subjects: 15
Study: 25759552

Group type: EXPERIMENTAL
Intervention: Combined intravariceal and esophageal mucosal sclerotherapy using small-volume sclerosant
Number of subjects: 38

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 38
Study: 23576329

Group type: EXPERIMENTAL
Intervention: Lower neighborhood income
Number of subjects: 40827

Group type: EXPERIMENTAL
Intervention: Adjusted neighborhood income
Number of subjects: 40827
Study: 21348897

Group type: EXPERIMENTAL
Intervention: Tumour infiltrating lymphocytes (TIL) treatment in 80 patients
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (not specified how many patients)
Number of subjects: 144
Study: 18468271

Group type: EXPERIMENTAL
Intervention: Orofacial myofunctional therapy (OMT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group with TMD (Group CTMD)
Number of subjects: 28
Study: 16224198

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (375-3000 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium carbonate (during double-blind phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 0
Study: 12964171

Group type: COMPARATOR
Intervention: Duloxetine 60 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine 120 mg/d (60 mg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine 40 mg/d (20 mg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine 80 mg/d (40 mg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine >/=60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study: 9537485

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (NO) at 100 ppm
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (NO) at 640 ppm
Number of subjects: 21

Group type: COMPARATOR
Intervention: No Inhaled Nitric Oxide
Number of subjects: 21
Study: 7635998

Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2619917

Group type: EXPERIMENTAL
Intervention: Ringer-lactate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Glucose at 5%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mixed-2 x 1
Number of subjects: 90
Study: 843186

Group type: EXPERIMENTAL
Intervention: Immediate psychotherapy treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 31546105

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI)
Number of subjects: 3519

Group type: COMPARATOR
Intervention: Relaxation program
Number of subjects: 3519

Group type: COMPARATOR
Intervention: Teaching as usual
Number of subjects: 3519
Study: 31077425

Group type: EXPERIMENTAL
Intervention: Genotype-guided tacrolimus doses (0.125 mg/kg/day for CYP3A5*1/*1, 0.1 mg/kg/day for *1/*3, 0.08 mg/kg/day for *3/*3)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Genotype-guided tacrolimus doses
Number of subjects: 125

Group type: COMPARATOR
Intervention: Conventional tacrolimus doses (0.1 mg/kg/day)
Number of subjects: 125
Study: 27904905

Group type: EXPERIMENTAL
Intervention: Idarucizumab (8 g as a 1-hour infusion)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Idarucizumab (4 g as a 5-minute infusion)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 25096689

Group type: EXPERIMENTAL
Intervention: Brief intervention (n=435)
Number of subjects: 868

Group type: COMPARATOR
Intervention: Enhanced care as usual (n=433)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 868

Group type: COMPARATOR
Intervention: Enhanced care as usual
Number of subjects: 868
Study: 22995632

Group type: EXPERIMENTAL
Intervention: Maudsley Model of Anorexia Nervosa Treatment for Adults (MANTRA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 72
Study: 19440025

Group type: EXPERIMENTAL
Intervention: Laser lithotripsy (LL)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Pneumatic lithotripsy (PL)
Number of subjects: 55
Study: 17251929

Group type: EXPERIMENTAL
Intervention: Native oat bran with 11.6 g native beta-glucans
Number of subjects: 9
Study: 15364150

Group type: EXPERIMENTAL
Intervention: Improved treatment reducing risk of restenosis and repeat revascularization
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Higher household income
Number of subjects: 1642
Study: 11272848

Group type: EXPERIMENTAL
Intervention: c‐SPHP 3 g per day
Number of subjects: 21

Group type: COMPARATOR
Intervention: c‐SPHP 0 g per day (placebo)
Number of subjects: 21
Study: 9817340

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 15 microg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 30 microg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 45 microg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 7847127

Group type: EXPERIMENTAL
Intervention: Computer-assisted cisternography (CAc)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both CAc and MRI
Number of subjects: 8
Study: 2679864

Group type: EXPERIMENTAL
Intervention: 2 g of elemental calcium per day
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 367057

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oxazepam 15 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31507088

Group type: EXPERIMENTAL
Intervention: Tenofovir gel provided through family planning clinics (intervention clinics), n = 189
Number of subjects: 372

Group type: COMPARATOR
Intervention: Tenofovir gel provided through CAPRISA research clinics (control clinics), n = 183
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Tenofovir gel provided through family planning clinics (intervention clinics)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Tenofovir gel provided through CAPRISA research clinics (control clinics)
Number of subjects: 372
Study: 28963158

Group type: EXPERIMENTAL
Intervention: Povidone iodine-alcohol followed by chlorhexidine gluconate-alcohol (PVI + CHG)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Povidone iodine-alcohol applied twice (PVI)
Number of subjects: 407
Study: 26193204

Group type: EXPERIMENTAL
Intervention: 3D ultrasound evaluation of fetal cerebral structures (choroid plexus, thalamus, cerebellum, hippocampus, Sylvian fissure)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Histological and immunohistochemical assessment
Number of subjects: 232
Study: 22867815

Group type: EXPERIMENTAL
Intervention: Discharged group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Admitted group
Number of subjects: 42
Study: 20624673

Group type: EXPERIMENTAL
Intervention: Isomalto-oligosaccharides (IO) 10 g/d for 8 weeks
Number of subjects: 13
Study: 19175374

Group type: EXPERIMENTAL
Intervention: Low GI diet
Number of subjects: 104

Group type: COMPARATOR
Intervention: CCE diet
Number of subjects: 104
Study: 16478762

Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel applied locally to the cervix 1 min before cervical manipulation/dilatation
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (KY Jelly) applied locally to the cervix 1 min before cervical manipulation/dilatation
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel
Number of subjects: 131
Study: 16939913

Group type: EXPERIMENTAL
Intervention: Cisplatin (30 mg/m(2))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Radiation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cisplatin administration
Number of subjects: 36
Study: 14992337

Group type: EXPERIMENTAL
Intervention: 0.5 microM RTX
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.0 microM RTX
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10484427

Group type: EXPERIMENTAL
Intervention: Inspired O2 fraction of 0.21
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inspired O2 fraction of 0.30
Number of subjects: 11
Study: 8954288

Group type: EXPERIMENTAL
Intervention: 20% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60% MVC
Number of subjects: 10
Study: 2026743

Group type: EXPERIMENTAL
Intervention: Traditional, high carbohydrate Pima Indian diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Modern, high fat western diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 12
Study: 6795043

Group type: EXPERIMENTAL
Intervention: Fat-rich diet (54 energy-% fat, 29 energy-% carbohydrate)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fat-poor diet (29 energy-% fat, 53 energy-% carbohydrate)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ordinary diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no dietary changes)
Number of subjects: 23
Study: 31654485

Group type: EXPERIMENTAL
Intervention: Daily disposable hydrogel contact lenses (etafilcon A)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Spectacle wearers
Number of subjects: 581
Study: 31642245

Group type: EXPERIMENTAL
Intervention: Low dose bortezomib (1.0-1.3 mg/m2) on day 1, day 4, day 8, and day 11, with 21 days as a chemotherapy cycle.
Number of subjects: 86

Group type: COMPARATOR
Intervention: High dose bortezomib (1.6 mg/m2) on day 1, day 8, day 15, and day 22, with 35 days as a chemotherapy cycle.
Number of subjects: 86
Study: 28065379

Group type: EXPERIMENTAL
Intervention: 24-gauge side-holes catheter
Number of subjects: 180

Group type: COMPARATOR
Intervention: 22-gauge end-hole catheter
Number of subjects: 180
Study: 25847610

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Canaloplasty
Number of subjects: 62
Study: 23778373

Group type: EXPERIMENTAL
Intervention: Surgery with postoperative physiotherapy (anterior cervical decompression and fusion plus physiotherapy program)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 63
Study: 21125288

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 154
Study: 19167662

Group type: EXPERIMENTAL
Intervention: education intervention
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: education intervention with booster
Number of subjects: 391

Group type: COMPARATOR
Intervention: no systematic intervention
Number of subjects: 391
Study: 17380809

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride and sodium hexametaphosphate dentifrice (Crest Pro‐Health)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Colgate Total + Whitening (positive control)
Number of subjects: 59
Study: 15119752

Group type: EXPERIMENTAL
Intervention: Epinastine 10 mg plus pseudoephedrine 120 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Loratadine 5 mg plus pseudoephedrine 120 mg
Number of subjects: 62
Study: 11694895

Group type: EXPERIMENTAL
Intervention: 60 degrees tilt for 45 min
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 80 degrees tilt for 45 min
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 60 degrees tilt drug-free
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 80 degrees tilt drug-free
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 60 degrees
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 80 degrees
Number of subjects: 201
Study: 9126518

Group type: EXPERIMENTAL
Intervention: Injury prevention campaign on Naxos involving trained local collaborators providing weekly visits and advice.
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group on Spetses with untrained collaborators visiting households.
Number of subjects: 349

Group type: COMPARATOR
Intervention: Overall injury incidence among target groups on Naxos vs Spetses.
Number of subjects: 349

Group type: COMPARATOR
Intervention: Home accidents incidence among target groups on Naxos vs Spetses.
Number of subjects: 349
Study: 8368543

Group type: EXPERIMENTAL
Intervention: 10 degrees reverse Trendelenburg tilt
Number of subjects: 30

Group type: COMPARATOR
Intervention: Horizontal position (Control)
Number of subjects: 30
Study: 3122880

Group type: EXPERIMENTAL
Intervention: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (up to 100 mg/kg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one with ascorbic acid
Number of subjects: 8

Group type: COMPARATOR
Intervention: Subcutaneous desferrioxamine (at comparable dose)
Number of subjects: 8
Study: 31146738

Group type: EXPERIMENTAL
Intervention: Decentralized health units
Number of subjects: 812

Group type: COMPARATOR
Intervention: Main hospital
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Convenient location, shorter commute times, shorter wait times
Number of subjects: 812
Study: 28474112

Group type: EXPERIMENTAL
Intervention: Transperineal laser ablation (TPLA)
Number of subjects: 18
Study: 25442234

Group type: EXPERIMENTAL
Intervention: Higher worksite neighborhood socioeconomic status (NSES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher density of residential units surrounding worksites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residential density
Number of subjects: 0
Study: 23939511

Group type: EXPERIMENTAL
Intervention: 30 mg/day baclofen
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 75 mg/day baclofen
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 30 mg/day baclofen (in pharmacokinetic and cue-reactivity component)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 75 mg/day baclofen (in pharmacokinetic and cue-reactivity component)
Number of subjects: 180
Study: 21560488

Group type: EXPERIMENTAL
Intervention: Siriraj Mite Allergen Vaccine (SMAV) Dp at 2,500 AU/ml
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Siriraj Mite Allergen Vaccine (SMAV) Dp at 10,000 AU/ml
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Siriraj Mite Allergen Vaccine (SMAV) Df at 10,000 AU/ml
Number of subjects: 54

Group type: COMPARATOR
Intervention: Commercial standardized mite allergen vaccine Dp at 2,500 AU/ml
Number of subjects: 54

Group type: COMPARATOR
Intervention: Commercial standardized mite allergen vaccine Df at all concentrations
Number of subjects: 54
Study: 19839877

Group type: EXPERIMENTAL
Intervention: RF (5 sessions, 1 every 10 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LED (8 sessions, 1 every 5 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RF and LED (3 RF sessions and 6 LED sessions, 1 RF and 2 LED every 5 days)
Number of subjects: 30
Study: 16750996

Group type: EXPERIMENTAL
Intervention: 3130C carriers of the MBL2 gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3130G carriers of the MBL2 gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonwild-type MBL2 carriers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wild-type MBL2 carriers
Number of subjects: 0
Study: 15466644

Group type: EXPERIMENTAL
Intervention: Candesartan, titrated to 32 mg QD
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study: 12225705

Group type: EXPERIMENTAL
Intervention: High nicotine cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active nicotine nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo nicotine nasal spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High nicotine cigarettes and Denicotinized cigarettes
Number of subjects: 0
Study: 9584032

Group type: EXPERIMENTAL
Intervention: Safe Dates program (treatment)
Number of subjects: 1886

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1886
Study: 7664561

Group type: EXPERIMENTAL
Intervention: Decompressive craniotomy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 53
Study: 2752600

Group type: EXPERIMENTAL
Intervention: Snack-HD (standard snack of about 400 Kcal)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control-HD (no snack)
Number of subjects: 13
Study: 31853116

Group type: EXPERIMENTAL
Intervention: Simulation laboratory with standardized patient
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 66
Study: 27739936

Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 450
Study: 26303812

Group type: EXPERIMENTAL
Intervention: 5As Team (5AsT) intervention
Number of subjects: 29
Study: 23593643

Group type: COMPARATOR
Intervention: G1: no treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G2: adhesive application
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G3: silane + adhesive
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G4: sandblasting (Al2O3) + adhesive
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G5: sandblasting (Al2O3) + silane + adhesive
Number of subjects: 50
Study: 21880994

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Enzyme-inducing AED (EIAED)
Number of subjects: 585

Group type: COMPARATOR
Intervention: No AED
Number of subjects: 585
Study: 19393405

Group type: EXPERIMENTAL
Intervention: Liquid alginate suspension
Number of subjects: 40